Trial Profile
A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of a Combination Oral Contraceptive Regimen (DR-103) for the Prevention of Pregnancy in Women.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Ethinylestradiol/levonorgestrel (Primary) ; Ethinylestradiol
- Indications Pregnancy
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Teva Womens Health
- 06 May 2013 Data will be presented at the 61st Annual Meeting of the American Congress of Obstetricians and Gynecologists (ACOG-2013), according to a Teva Women's Health media release.
- 13 Nov 2012 Results were presented at the 68th Annual Meeting of the American Society of Reproductive Medicine (ASRM).
- 15 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.